EM
EMD.AU Emyria Ltd
- Market cap
- AUD 31.5M
- P/E
- -
- P/B
- 3.56x
- ROE
- -69.1%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is EMD.AU undervalued?
Graham numberThe Graham number of Emyria Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Emyria Ltd fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-69.1%), below 10%.
ROA 0/1
Return on assets (-53.2%) is below the industry median (-45.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-18.0%) is below the industry median (18.9%).
Revenue Growth 2/2
Revenue grew 34.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (8.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (3.6x) is below the industry median (5.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Emyria Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Emyria Ltd
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under th…
Full company profileEmyria Ltd financial statements
Emyria Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 110K | 1.01M | 1.98M | 1.82M | 1.59M | 2.20M | 1.39M | 3.88M |
| Gross Profit | - | -1.62M | -2.79M | -1.58M | -4.41M | -3.32M | -168K | 24.5K | -3.66M |
| Operating Income | -64.3K | -2.71M | -5.63M | -5.71M | -8.54M | -7.12M | -6.90M | -2.65M | -6.27M |
| EBITDA | -64.3K | -2.58M | -4.80M | -4.49M | -8.03M | -6.69M | -13.0M | -2.03M | -5.81M |
| Net Income | -64.3K | -2.68M | -5.24M | -4.91M | -7.33M | -5.13M | -11.5M | -3.14M | -6.11M |
| EPS | 0.00 | -0.01 | -0.03 | -0.02 | -0.03 | -0.02 | -0.03 | -0.01 | -0.01 |
| Balance Sheet | |||||||||
| Total Assets | 3.06M | 3.52M | 5.06M | 9.06M | 8.25M | 10.2M | 5.43M | 6.62M | 11.5M |
| Total Liabilities | 250K | 3.03M | 1.28M | 1.88M | 1.93M | 3.37M | 3.00M | 1.31M | 2.65M |
| Shareholders' Equity | 2.81M | 500K | 3.78M | 7.18M | 6.32M | 6.79M | 2.43M | 5.31M | 8.85M |
| Cash & Short-term Investments | 3.04M | 2.61M | 3.69M | 6.53M | 3.88M | 2.73M | 1.57M | 3.57M | 7.29M |
| Total Debt | - | 3.15M | 611K | 950K | 633K | 1.27M | 1.72M | 613K | 787K |
| Cash Flow | |||||||||
| Operating Cash Flow | -20.8K | -2.59M | -4.45M | -3.94M | -5.43M | -3.77M | -4.28M | -2.70M | -4.56M |
| Capital Expenditure | 845K | 845K | 202K | 661K | 2.03M | 3.23M | 159K | 13.9K | 366K |
| Free Cash Flow | -20.8K | -3.44M | -4.65M | -4.60M | -7.46M | -7.01M | -4.44M | -2.72M | -4.92M |
| Ratios | |||||||||
| ROE | -2.3% | -537.1% | -138.5% | -68.3% | -115.9% | -75.5% | -472.3% | -59.2% | -69.1% |
| ROA | -2.1% | -76.1% | -103.4% | -54.2% | -88.8% | -50.5% | -211.1% | -47.5% | -53.2% |
| Net Profit Margin | - | -2,441.0% | -516.9% | -248.3% | -402.1% | -322.2% | -520.1% | -225.3% | -157.6% |
| Debt to Equity | - | 6.31x | 0.16x | 0.13x | 0.10x | 0.19x | 0.71x | 0.12x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Emyria Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 62.6K | 0.00 | - |
| 2022 | AUD 768K | 0.00 | - |
| 2021 | AUD 342K | 0.00 | - |
| 2020 | AUD 527K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Emyria Ltd
- Insiders 25.82%
- Institutions 0.00%
- Public & others 74.18%
- Shares outstanding 807M
- Free float 601M
Emyria Ltd company profile
- Company name
- Emyria Ltd
- Ticker
- EMD.AU
- ISIN
- AU0000073645
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- June
- Address
- Level 1, 516 Hay Street, Subiaco, WA, Australia, 6008
- Phone
- 61 8 6559 2800
- Website
- emyria.com
About Emyria Ltd
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.
Emyria Ltd management
5- Mr. Gregory HutchinsonExecutive Chairman
- Dr. Michael WinloChief Scientific Officer & Executive Director
- Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.Chief Financial Officer
- Dr. Alistair VickeryExecutive Medical Director & Director
- Mary-Ann RennieHead of Corporate Operations